Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David Andrew Sallman, Monzr M. Al Malki, Adam Steven Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence J. Bradley, Ian W. Flinn, Daniel Aaron Pollyea, Suman Kambhampati, Tiffany N. Tanaka, Joshua F. Zeidner, Guillermo Garcia-Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark Chao, Carol Elaine O'Hear, Indu Lal, Paresh Vyas, Naval Guastad Daver
Institutions: Moffitt Cancer Center, City Of Hope National Medical Center, OU Health, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Roswell Park Comprehensive Cancer Center, Columbia University Irving Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, Tennessee Oncology, University of Colorado Anschutz, Research Medical Center, Moores Cancer Center, UNC Lineberger Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of California, Irvine, Gilead Sciences (United States), University of Oxford, MRC Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Gilead Sciences
OpenAlex ID: W4286294929